Aegis Wealth Management LLC Lowers Stock Holdings in Johnson & Johnson $JNJ

Aegis Wealth Management LLC lessened its position in Johnson & Johnson (NYSE:JNJ) by 8.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,386 shares of the company’s stock after selling 330 shares during the quarter. Aegis Wealth Management LLC’s holdings in Johnson & Johnson were worth $562,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC increased its holdings in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after purchasing an additional 6,332 shares during the period. Wealth Group Ltd. acquired a new position in shares of Johnson & Johnson during the first quarter worth about $218,000. Smart Money Group LLC increased its stake in shares of Johnson & Johnson by 6.5% during the first quarter. Smart Money Group LLC now owns 6,687 shares of the company’s stock worth $1,109,000 after buying an additional 407 shares during the period. Diversify Wealth Management LLC lifted its stake in Johnson & Johnson by 16.8% in the first quarter. Diversify Wealth Management LLC now owns 23,008 shares of the company’s stock worth $3,587,000 after acquiring an additional 3,317 shares during the last quarter. Finally, Gateway Wealth Partners LLC grew its holdings in Johnson & Johnson by 17.4% during the 1st quarter. Gateway Wealth Partners LLC now owns 2,729 shares of the company’s stock worth $453,000 after acquiring an additional 404 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 0.3%

Shares of JNJ stock opened at $186.50 on Monday. The business’s fifty day moving average price is $184.25 and its 200 day moving average price is $168.80. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The firm has a market capitalization of $449.34 billion, a PE ratio of 18.00, a P/E/G ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.48.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Analysts Set New Price Targets

Several research firms have recently issued reports on JNJ. Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 22nd. Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Raymond James Financial raised their target price on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 15th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. Finally, The Goldman Sachs Group lifted their target price on Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday, October 9th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $199.05.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.